BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Approves Celltrion, Inc. to Manufacture ORENCIA(R) (abatacept)


12/18/2007 7:08:29 AM

INCHEON, South Korea, Dec. 18 /PRNewswire/ -- Celltrion, Inc., a leading Korean biopharmaceutical company, announces that it has received approval from the U.S. Food and Drug Administration (FDA) to serve as a contract manufacturer to produce ORENCIA(R) (abatacept), a novel biologic agent for the treatment of rheumatoid arthritis, developed by Bristol-Myers Squibb Company . The Supplemental Biological License Application (sBLA) was submitted by Bristol-Myers Squibb Company to meet expected long-term demand for ORENCIA(R).

Celltrion is the largest biopharmaceutical manufacturing facility in the Asia-Pacific region, and the only Asian large-scale cell-culture contract manufacturing facility which has successfully obtained approval from the U.S. FDA.

"We are pleased to continue our strategic business partnership with Bristol-Myers Squibb. Achieving sBLA approval from the FDA to manufacture ORENCIA(R) is an important milestone that reinforces our vision to become a fully integrated global biotechnology company," said Jung-Jin Seo, Chairman and Chief Executive Officer of Celltrion. "Celltrion is dedicated to working with our business partners to exceed their quality requirements while providing manufacturing value. It is our commitment to quality service that will attract other global biopharmaceutical companies to our manufacturing capabilities."

About Celltrion, Inc.

Celltrion, established in 2002, is a contract manufacturing organization with a headquarters in Incheon, South Korea. Celltrion, an emerging leader in the biopharmaceutical industry, is dedicated to providing high quality services to accelerate product development, while offering scalable manufacturing capabilities for our clients and business partners. Celltrion is also investing in research and development of its own products, as well as licensing from biopharmaceutical research companies throughout the world, in order to develop into a fully integrated biotechnology company. Further information can be found on our website http://www.celltrion.com.

CONTACT: Jae Chung, Vice President, Business Development of Celltrion,
Inc., +1-415-290-9826

Web site: http://www.celltrion.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES